{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:25Z","timestamp":1792788925277,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S","id":[{"id":"https:\/\/ror.org\/0435rc536","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Semaglutide reduced kidney outcome risk across broad CKD severity strata (eGFR; albuminuria).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Reduced risk for all-cause death also carried through strata of CKD severity.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In a population with type 2 diabetes, semaglutide improved kidney and survival outcomes irrespective of CKD severity, including advanced CKD.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and CKD in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial. The aim of the present analyses was to quantify these benefits across broad strata of CKD severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      FLOW was a double-blind, randomized, placebo-controlled trial (median follow-up 3.4 [interquartile range, 2.9\u20134.0] years). Participants with T2D and eGFR 50\u201375 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and urine albumin-to-creatinine ratio (UACR) &gt;300 to &lt;5000 mg\/g, or eGFR 25 to &lt;50 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and UACR &gt;100 to &lt;5000 mg\/g, were randomized to subcutaneous semaglutide 1 mg once-weekly or placebo. Subgroups were categorized by baseline eGFR (&lt;30 to \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) or UACR (&lt;100 to \u22652000 mg\/g) to assess the primary outcome and individual components (\u226550% eGFR decline, eGFR &lt;15 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , dialysis, kidney transplant, and death due to kidney or cardiovascular causes), all-cause death, eGFR, and UACR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the mean\u00b1SD eGFR was 47\u00b115 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , and the median (5th\u201395th percentile) UACR was 568 (51\u20133225) mg\/g. The primary outcome occurred in 19% (331 of 1767) versus 23% (410 of 1766) with semaglutide treatment versus placebo (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.66 to 0.88). Death occurred in 13% (227 of 1767) versus 16% (279 of 1766), respectively (HR, 0.80; 95% CI, 0.67 to 0.95). Across eGFR and UACR subgroups, HRs for the primary outcome remained consistent (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      for interaction 0.83 and 0.42, respectively). For death, HRs were consistent among eGFR subgroups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      for interaction 0.54), but the HR was lowest (0.47; 95% CI, 0.31 to 0.70) for those with UACR \u22652000 mg\/g (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      for interaction 0.02). Estimated treatment effects on eGFR and UACR were generally consistent among subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide reduced risks of major kidney disease events and all-cause death across wide-ranging categories of baseline eGFR and UACR, supporting semaglutide treatment in T2D throughout the spectrum of CKD severity represented in FLOW, including advanced CKD.<\/jats:p>\n                    <jats:p>Clinical Trial registry name and registration number: NCT03819153.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000974","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:03:11Z","timestamp":1771434191000},"page":"841-851","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of Washington School of Medicine, Seattle, Washington"},{"name":"Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3154-5332","authenticated-orcid":false,"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Centre, M\u00fcnchen, Germany"},{"name":"University Hospital, Friedrich-Alexander University, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel M.","family":"Mayrdorfer","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Bagsv\u00e6rd, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-9591","authenticated-orcid":false,"given":"Brian","family":"Rayner","sequence":"additional","affiliation":[{"name":"Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0397","authenticated-orcid":false,"given":"Giuseppe","family":"Pugliese","sequence":"additional","affiliation":[{"name":"University of Rome La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-1389","authenticated-orcid":false,"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[{"name":"AdventHealth Translational Research Institute, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-2148","authenticated-orcid":false,"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford Center for Clinical Research (SCCR), Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-984X","authenticated-orcid":false,"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Kawasaki Ika Daigaku, Kurashiki, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole K.","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Bagsv\u00e6rd, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gumprecht","sequence":"additional","affiliation":[{"name":"Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Bosch-Traberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Bagsv\u00e6rd, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Herlev, Denmark"},{"name":"Kobenhavns Universitet, Kobenhavn, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FLOW Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1-20261023","doi-asserted-by":"crossref","first-page":"110945","DOI":"10.1016\/j.diabres.2023.110945","article-title":"Erratum to IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"204","author":"Sun","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"B2-20261023","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"15","key":"B3-20261023","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMc2207018","article-title":"Incidence of chronic kidney disease among adults with diabetes, 2015-2020","volume":"387","author":"Tuttle","year":"2022","journal-title":"N Engl J Med."},{"issue":"3","key":"B4-20261023","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health."},{"issue":"1","key":"B5-20261023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)."},{"issue":"2","key":"B6-20261023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"9","key":"B7-20261023","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B8-20261023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"22","key":"B9-20261023","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation."},{"issue":"10","key":"B10-20261023","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"B11-20261023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"B12-20261023","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int."},{"issue":"2","key":"B13-20261023","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"24","key":"B14-20261023","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA."},{"issue":"13","key":"B15-20261023","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"1","key":"B16-20261023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"B17-20261023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int."},{"issue":"4","key":"B18-20261023","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","article-title":"Chronic kidney disease and the risk of end-stage renal disease versus death","volume":"26","author":"Dalrymple","year":"2011","journal-title":"J Gen Intern Med."},{"issue":"1","key":"B19-20261023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2215\/CJN.0000000857","article-title":"A real-world cohort study of the risks of kidney failure and death in diabetes","volume":"21","author":"Tuttle","year":"2026","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B20-20261023","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"4S","key":"B22-20261023","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"issue":"9","key":"B23-20261023","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"B24-20261023","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"B25-20261023","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/dc23-0261","article-title":"Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care."},{"issue":"6","key":"B26-20261023","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"issue":"2","key":"B27-20261023","doi-asserted-by":"crossref","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"issue":"4","key":"B28-20261023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B29-20261023","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol."},{"issue":"7","key":"B30-20261023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol."},{"issue":"3","key":"B31-20261023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int."},{"issue":"1","key":"B32-20261023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B33-20261023","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"issue":"1-2","key":"B34-20261023","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000529374","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:00:33Z","timestamp":1792771233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000974","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"2025-10-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}